9.33
Theravance Biopharma Inc stock is traded at $9.33, with a volume of 112.92K.
It is up +2.08% in the last 24 hours and down -0.75% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$9.13
Open:
$9.19
24h Volume:
112.92K
Relative Volume:
0.49
Market Cap:
$455.13M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-10.14
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
+8.00%
1M Performance:
-0.75%
6M Performance:
+5.91%
1Y Performance:
-1.48%
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TBPH
Theravance Biopharma Inc
|
9.33 | 455.13M | 62.02M | -45.65M | -9.60M | -0.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.62 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
583.71 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
600.69 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.00 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.42 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Apr-12-24 | Initiated | BTIG Research | Buy |
Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
May-23-22 | Initiated | SVB Leerink | Outperform |
Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jul-07-20 | Initiated | JP Morgan | Overweight |
Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
May-13-20 | Initiated | Cowen | Outperform |
Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
Oct-29-19 | Initiated | H.C. Wainwright | Buy |
Mar-29-18 | Resumed | Piper Jaffray | Overweight |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
May-11-17 | Reiterated | Needham | Buy |
Dec-21-16 | Initiated | Needham | Buy |
Nov-03-16 | Initiated | Piper Jaffray | Overweight |
Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jun-20-16 | Initiated | Guggenheim | Buy |
Jun-20-16 | Reiterated | Leerink Partners | Outperform |
May-12-16 | Initiated | Leerink Partners | Outperform |
May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Alliancebernstein L.P. - Defense World
(TBPH) Trading Signals - news.stocktradersdaily.com
Vanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Position Trimmed by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Raises Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
KLP Kapitalforvaltning AS Acquires New Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
American Century Companies Inc. Acquires 8,289 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma at Jones Conference: Strategic Growth and Future Prospects - Investing.com Canada
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire
Teacher Retirement System of Texas Takes $103,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares - MSN
Theravance Biopharma to Participate in an Upcoming Investor Conference - Longview News-Journal
Exclusive Access: Theravance Biopharma Leadership Reveals Strategy at Jones Healthcare Conference - Stock Titan
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Yahoo Finance
Charles Schwab Investment Management Inc. Has $2.77 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PR Newswire
Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Brokerages - Defense World
Q1 EPS Forecast for Theravance Biopharma Reduced by Analyst - Defense World
(TBPH) Investment Analysis - news.stocktradersdaily.com
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next? - Defense World
Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha
Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Theravance Biopharma, Inc. to Host Earnings Call - ACCESS Newswire
Zacks Research Brokers Lower Earnings Estimates for TBPH - Armenian Reporter
What is Zacks Research’s Forecast for TBPH Q1 Earnings? - Defense World
Where are the Opportunities in (TBPH) - news.stocktradersdaily.com
Equities Analysts Issue Forecasts for TBPH FY2028 Earnings - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
HC Wainwright Reiterates Buy Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma Reports Strong Q4 2024 Earnings - TipRanks
Investor Network: Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Research Analysts Issue Forecasts for TBPH FY2024 Earnings - Defense World
Theravance Biopharma (NASDAQ:TBPH) Releases Earnings Results, Misses Estimates By $0.26 EPS - MarketBeat
Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey
FY2024 Earnings Forecast for TBPH Issued By HC Wainwright - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada
Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
What is HC Wainwright’s Estimate for TBPH FY2028 Earnings? - Defense World
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates - MSN
Theravance Biopharma Reports Record 2024 Financial Results - TipRanks
Theravance Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire
Theravance Biopharma Inc Reports Q4 2024 Earnings: YUPELRI Sales Reach $66.7 Million, TRELEGY Milestone Achieved - GuruFocus
Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 20 - GuruFocus
Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result - Yahoo Finance
Theravance Biopharma: Strategic Milestones and Revenue Forecasts Justify Buy Rating - TipRanks
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):